Skip to main content

Clarity Pharmaceuticals Health Care
Biotech Cancer Healthcare North America Pharmaceuticals

$0.700 0.005 (0.72%)

High

$0.72

Low

$0.70

Trades

33

Turnover

$39,512

Volume

56,305
30 June 2023 at 4:10pm
If you were already registered, log in here.
CU6 Announcements on Price Chart

Latest Announcements

Headline Date
Cleansing Notice 28 June 2023 at 1:45pm
Application for quotation of securities - CU6 28 June 2023 at 1:40pm
Clarity Establishes US Center of Excellence for Research 28 June 2023 at 9:30am
Northstar Achieves Key Production Milestones 27 June 2023 at 8:55am
Cleansing Notice 20 June 2023 at 1:25pm
Application for quotation of securities - CU6 20 June 2023 at 1:25pm
COMBAT theranostic prostate cancer trial commences in the US 20 June 2023 at 9:45am
Clarity expands supply of Cu-64 for Phase III trials 14 June 2023 at 9:20am
Presentation at Jefferies Healthcare Conference 13 June 2023 at 9:30am
Recruitment complete for Phase II prostate cancer trial 7 June 2023 at 8:50am
Clarity to present at ASCO and SNMMI 2023 Annual Meetings 26 May 2023 at 1:45pm
Notification regarding unquoted securities - CU6 25 May 2023 at 3:45pm
Theranostic prostate cancer trial advances to cohort 2 24 May 2023 at 10:15am
Final Director's Interest Notice - O'Bryan Tear 16 May 2023 at 10:35am
Initial Director's Interest Notice 2 May 2023 at 5:30pm
Quarterly Activities/Appendix 4C Cash Flow Report 28 April 2023 at 2:05pm
Clarity Receives $6.7 million R&D Tax Incentive Refund 18 April 2023 at 1:10pm
Notification of cessation of securities - CU6 11 April 2023 at 5:50pm
Notification regarding unquoted securities - CU6 5 April 2023 at 12:30pm
Clarity update on NorthStar copper-67 production 4 April 2023 at 10:20am
Cleansing Notice 28 March 2023 at 3:30pm
Application for quotation of securities - CU6 28 March 2023 at 9:45am
Clarity Corporate Presentation 13 March 2023 at 1:20pm
Clarity confirms no supply interruptions 2 March 2023 at 3:50pm
World leading expert in copper-67 joins Clarity SAB 1 March 2023 at 11:30am
Half Yearly Report and Accounts 28 February 2023 at 5:05pm
Appendix 4D 28 February 2023 at 4:45pm
Change of Director's Interest Notice - Biggin 21 February 2023 at 2:35pm
Cleansing Notice 21 February 2023 at 11:15am
Notification regarding unquoted securities - CU6 21 February 2023 at 11:15am
Application for quotation of securities - CU6 21 February 2023 at 11:15am
50% recruitment milestone for NET diagnostic Phase II trial 16 February 2023 at 9:30am
PROPELLER Trial Results 14 February 2023 at 9:45am
Ceasing to be a substantial holder 13 February 2023 at 5:05pm
Diagnostic prostate cancer trial reaches recruitment target 9 February 2023 at 10:15am
Application for quotation of securities - CU6 2 February 2023 at 5:15pm
Changes to Clarity Board of Directors 1 February 2023 at 10:25am
Quarterly Activities/Appendix 4C Cash Flow Report 31 January 2023 at 10:20am
Notification regarding unquoted securities - CU6 30 January 2023 at 12:35pm
Positive topline results from SAR-bisPSMA diagnostic trial 14 December 2022 at 9:55am
Cleansing Notice 13 December 2022 at 10:50am
Application for quotation of securities - CU6 13 December 2022 at 10:45am
Change of Director's Interest Notices - Taylor and Biggin 9 December 2022 at 5:15pm
Notification regarding unquoted securities - CU6 9 December 2022 at 12:15pm
Clarity Corporate Presentation & Webinar 2 December 2022 at 10:10am
Clarity Corporate Presentation & Webinar 2 December 2022 at 10:10am
Results of Meeting 24 November 2022 at 12:00pm
Managing Director's Presentation to AGM 24 November 2022 at 9:20am
Chairman's Address to Shareholders 24 November 2022 at 9:10am
ESG Report 23 November 2022 at 3:55pm
If you were already registered, log in here.